Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation
Top Cited Papers
Open Access
- 19 February 2008
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (3), 679-687
- https://doi.org/10.1111/j.1600-6143.2007.02126.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis: (Paris, France, January 12–14, 2006)Journal of Hepatology, 2006
- Hepatitis C Recurrence After Liver Transplantation: Viral and Histologic Response to Full-Dose Peg-Interferon and RibavirinAmerican Journal of Transplantation, 2006
- Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis CLiver Transplantation, 2006
- Treatment of Hepatitis C after Liver TransplantationClinics in Liver Disease, 2005
- Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantationJournal of Hepatology, 2005
- Treatment of Established Recurrent Hepatitis C in Liver-Transplant Recipients with Pegylated Interferon-alfa-2b and Ribavirin TherapyTransplantation, 2004
- Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinationJournal of Hepatology, 2004
- Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1Transplantation, 2004
- Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on liver transplantation and hepatitis CLiver Transplantation, 2003
- Hepatitis C and liver transplantationJournal of Hepatology, 2001